Coagulation monitor maker HemoSense prices IPO at $19.25m:
This article was originally published in Clinica
HemoSense, the San Jose, California-based maker of the INRatio point-of-care device for patients taking oral anticoagulants to monitor the clotting time of their blood, has priced its initial public offering. It plans to offer 3.5 million shares at $5.50 each, for proceeds of $19.25m. Underwriters also have an option to purchase an additional 525,000 shares to cover over-allotments. The stock will be listed on the American Stock Exchange.